Botanix Pharmaceuticals Limited
BXPHF
$0.25
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -0.16% | 2.26% | 2,715.15% | 2,639.90% | -89.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.16% | 2.26% | 2,715.15% | 2,639.90% | -89.91% |
| Cost of Revenue | 23.53% | 26.41% | 314.44% | 304.04% | -80.96% |
| Gross Profit | -38.45% | -41.68% | -67.89% | -63.71% | 56.83% |
| SG&A Expenses | 510.45% | 524.69% | 126.17% | 120.59% | 69.76% |
| Depreciation & Amortization | 13,392.59% | 13,278.57% | -32.59% | -34.06% | -50.91% |
| Other Operating Expenses | -- | -- | -49.03% | -50.28% | -- |
| Total Operating Expenses | 447.84% | 460.63% | 119.08% | 113.69% | -29.72% |
| Operating Income | -478.46% | -491.97% | -85.00% | -80.43% | -18.74% |
| Income Before Tax | -464.91% | -478.11% | -81.91% | -77.42% | -17.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -464.91% | -478.11% | -81.91% | -77.42% | -17.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -464.91% | -478.11% | -81.91% | -77.42% | -17.85% |
| EBIT | -478.46% | -491.97% | -85.00% | -80.43% | -18.74% |
| EBITDA | -459.10% | -472.15% | -84.02% | -79.48% | -18.81% |
| EPS Basic | -358.33% | -375.00% | -50.00% | -50.00% | 20.00% |
| Normalized Basic EPS | -337.50% | -350.00% | -57.14% | -37.50% | 11.11% |
| EPS Diluted | -358.33% | -375.00% | -50.00% | -50.00% | 20.00% |
| Normalized Diluted EPS | -337.50% | -350.00% | -57.14% | -37.50% | 11.11% |
| Average Basic Shares Outstanding | 26.29% | 26.29% | 21.62% | 21.62% | 40.84% |
| Average Diluted Shares Outstanding | 26.29% | 26.29% | 21.62% | 21.62% | 40.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
